sickle cell disease

MedicAlert Foundation, SCDAA, and Fulcrum Therapeutics launch three-year partnership to improve emergency department access to sickle cell patients' critical care information via smart medical ID cards.

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.

Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.